Framework to Evaluate Advanced Development and FDA Approval Potential of MCMs

Overview

A conceptual framework was developed to assess the feasibility of generating pivotal data supporting FDA approval of vaccines and therapeutics for emerging viral pathogens. The framework identifies eight key factors influencing advanced development and regulatory clearance, guiding BARDA's portfolio decisions to optimize resource allocation and preparedness.

Background

BARDA supports advanced development and regulatory approval of medical countermeasures (MCMs) addressing chemical, biological, radiological, nuclear threats, and emerging infectious diseases. Emerging viral pathogens pose ongoing national security risks, necessitating efficient prioritization of MCM development due to numerous threats and limited resources. Regulatory approval pathways include traditional Phase 3 trials, Accelerated Approval based on surrogate endpoints, and the Animal Rule for scenarios where human efficacy trials are infeasible or unethical. Early FDA engagement and a structured assessment framework are essential to streamline MCM development and approval.

Data Highlights

The framework was applied to seven prioritized emerging viral pathogens to evaluate the feasibility of advanced development and FDA approval of vaccines and therapeutics. It identified eight central factors impacting the ability to generate pivotal data, highlighting that vaccine development currently appears more feasible than therapeutics for these pathogens. Regulatory pathways remain product- and context-specific, emphasizing the need for tailored strategies.

Key Findings

• Eight key factors were identified as central to assessing feasibility of advanced development and FDA approval of MCMs.
• The framework supports prioritization by highlighting candidates with the highest potential for FDA approval within existing regulatory paradigms.
• Vaccine development is generally more feasible than therapeutics for the emerging pathogens assessed.
• Regulatory pathways include traditional Phase 3 trials, Accelerated Approval, and the Animal Rule, each with distinct requirements.
• Early and close consultation with FDA is critical to define appropriate regulatory strategies for MCM candidates.
• The framework promotes efficient resource allocation and timely availability of MCMs during public health emergencies.

Clinical Implications

This framework provides a structured approach to evaluate and prioritize MCM candidates for emerging viral pathogens, facilitating efficient use of resources and accelerating regulatory approval processes. Clinicians and public health officials can anticipate more timely availability of effective vaccines and therapeutics through informed portfolio management and early regulatory engagement. Understanding the feasibility of different regulatory pathways aids in strategic planning for MCM development.

Conclusion

The conceptual framework offers a proactive tool to guide BARDA's investment decisions and regulatory strategies, enhancing national preparedness against emerging viral threats. By systematically assessing development feasibility, it supports the advancement of MCMs from research through FDA approval.

References

1. BARDA Mission and Portfolio Overview
2. FDA Regulatory Pathways: Traditional, Accelerated Approval, Animal Rule
3. Emerging Viral Pathogens and National Security Threats
4. BARDA Strategy for Emerging Viral Pathogens